Skip to main content

Table 2 Baseline clinical and pathological characteristics of validation cohort A

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

Clinical variable

 

No response

Response

OR (95% CI)a

N (%)

 

54 (34.4)

103 (65.6)

Age (year)

 

34.7 ± 14.7

34.3 ± 15.3

1.005 (0.98–1.03)

Gender (male %)

 

37 (68.5)

60 (58.3)

0.62 (0.31–1.27)

MAP (mmHg)

 

95.4 ± 16.5

92.7 ± 11.9

1.02 (0.99–1.04)

BMI (kg/m2)

 

24.4 ± 3.7

23.7 ± 3.7

1.04 (0.94–1.14)

Ln(Pro) (g/24 h)

 

1.8 ± 0.4

1.8 ± 0.4

1.17 (0.52–2.60)

Albumin (g/L)

 

16.5 ± 6.8

16.1 ± 5.6

1.01 (0.96–1.07)

eGFR (mL/min/1.73 m2)

 

81.9 ± 37.5

99.1 ± 27.5

0.98 (0.97–0.99)#

TG (mmol/L)

 

4.3 ± 3.9

3.6 ± 3.4

1.05 (0.96–1.16)

TC (mmol/L)

 

10.6 ± 3.6

10.5 ± 4.1

1.001 (0.92–1.09)

Ln(β2-MG/uCr) (ug/mmoL)

 

4.6 ± 1.7

3.2 ± 1.5

1.76 (1.30–2.37)#

Pathological evaluation

Score

No response

Response

OR (95% CI)

FSGS (%)

 

46 (45.5)

55 (54.5)

5.02(2.16–11.7)#

MCD (%)

 

8 (14.3)

48 (85.7)

0.20(0.09–0.46)#

Global sclerosis (%)

0

27 (50.0)

74 (71.8)

-ref-

1

23 (42.6)

28 (27.2)

2.25(1.11–4.56)*

Segmental sclerosis (%)

0

10 (18.5)

59 (57.3)

-ref-

1

40 (74.1)

43 (41.7)

5.49(2.47–12.17)#

Interstitial fibrosis (%)

0

8 (14.8)

43 (35.0)

-ref-

1

42 (77.8)

59 (57.3)

3.83(1.63–8.97)#

Inflammatory cell infiltration (%)

0

14 (25.9)

47 (45.6)

-ref-

1

36 (66.7)

55 (53.4)

2.20(1.06-–4.56)*

Tubular atrophy (%)

0

12 (22.2)

46 (44.7)

-ref-

1

38 (70.4)

56 (54.4)

2.60(1.22–5.55)*

Vascular lesion (%)

0

29 (53.7)

62 (60.2)

-ref-

1

20 (37.0)

40 (38.8)

1.07 (0.53–2.14)

  1. MAP: mean arterial pressure; BMI: body mass index; Ln(Pro): natural logarithm of urine protein; eGFR: estimated glomerular filtration rate; TG: triglyceride; TC: total cholesterol; β2-MG: β2-microglobulin; α1-MG: α1-microglobulin; uCr: urinary creatinine; FSGS: focal segmental glomerulosclerosis; MCD: minimal change disease; IgAN: Immunoglobulin A nephropathy; MN: membranous nephropathy
  2. a Adjusted by age and gender
  3. *P < 0.05, #P < 0.01